Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER_GOV 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Osteoporosis 5Prostatic Neoplasms 3Breast Neoplasms 3Hypogonadism 2Uterine Cervical Neoplasms 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Genetic Diseases, Inborn 1

Interventions

Cisplatin 178Paclitaxel 79Radiotherapy 76Carboplatin 70Brachytherapy 69pembrolizumab 63Bevacizumab 40Gemcitabine 28Radiation 27Topotecan 26Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 25Nivolumab 22Colposcopy 22human papillomavirus vaccine, L1 type 16, 18 21Magnetic Resonance Spectroscopy 21Drug Therapy 20atezolizumab 19Platinum 19Papillomavirus Vaccines 18Radiotherapy, Intensity-Modulated 17Docetaxel 17Taxes 16Cyclophosphamide 16Biopsy 16Early Intervention, Educational 151,2-diaminocyclohexaneplatinum II citrate 15Methods 14Blood Specimen Collection 14fludarabine 13Injections 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Uterine Cervical Neoplasms × Alendronate × Clear all
NCT07245381 2025-11-24

Alendronate to Reduce Pelvic Insufficiency Fractures in Cervical Cancer Patients Undergoing Chemoradiation

Sheba Medical Center

Phase 1/2 Not yet recruiting
65 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡